JP2022540620A5 - - Google Patents

Info

Publication number
JP2022540620A5
JP2022540620A5 JP2022501205A JP2022501205A JP2022540620A5 JP 2022540620 A5 JP2022540620 A5 JP 2022540620A5 JP 2022501205 A JP2022501205 A JP 2022501205A JP 2022501205 A JP2022501205 A JP 2022501205A JP 2022540620 A5 JP2022540620 A5 JP 2022540620A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
seq
binding fragment
tslp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022501205A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022540620A (ja
JP7597784B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/041642 external-priority patent/WO2021007533A1/en
Publication of JP2022540620A publication Critical patent/JP2022540620A/ja
Publication of JP2022540620A5 publication Critical patent/JP2022540620A5/ja
Application granted granted Critical
Publication of JP7597784B2 publication Critical patent/JP7597784B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022501205A 2019-07-11 2020-07-10 胸腺間質性リンパ球新生因子(tslp)受容体シグナル伝達に干渉する薬剤 Active JP7597784B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962873051P 2019-07-11 2019-07-11
US62/873,051 2019-07-11
PCT/US2020/041642 WO2021007533A1 (en) 2019-07-11 2020-07-10 Agents that interfere with thymic stromal lymphopoietin (tslp)-receptor signaling

Publications (3)

Publication Number Publication Date
JP2022540620A JP2022540620A (ja) 2022-09-16
JP2022540620A5 true JP2022540620A5 (cg-RX-API-DMAC7.html) 2023-06-19
JP7597784B2 JP7597784B2 (ja) 2024-12-10

Family

ID=74114844

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022501205A Active JP7597784B2 (ja) 2019-07-11 2020-07-10 胸腺間質性リンパ球新生因子(tslp)受容体シグナル伝達に干渉する薬剤

Country Status (8)

Country Link
US (1) US12435131B2 (cg-RX-API-DMAC7.html)
EP (1) EP3996747A4 (cg-RX-API-DMAC7.html)
JP (1) JP7597784B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220033504A (cg-RX-API-DMAC7.html)
CN (1) CN114401741A (cg-RX-API-DMAC7.html)
AU (1) AU2020311432A1 (cg-RX-API-DMAC7.html)
CA (1) CA3147044A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021007533A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022166739A1 (en) * 2021-02-04 2022-08-11 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing thymic stromal lymphopoietin and uses thereof
CN117209604B (zh) * 2021-12-02 2024-03-22 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CA3244178A1 (en) * 2021-12-24 2023-06-29 Inmagene Pte. Ltd. NEW ANTI-TSLP ANTIBODY
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
IL323448A (en) * 2023-02-23 2025-12-01 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Monoclonal antibody preparation targeting tslp
CN121443639A (zh) * 2023-06-22 2026-01-30 派拉冈医疗公司 结合tslp和tslpr的抗体及其使用方法
WO2025195445A1 (zh) * 2024-03-21 2025-09-25 北京三诺佳邑生物技术有限责任公司 特异性结合light和tslp的多特异性抗体以及组合物及其应用
CN120721972A (zh) * 2024-03-27 2025-09-30 北京智仁美博生物科技有限公司 鉴定抗人tslp双特异性抗体的方法
WO2025214333A1 (zh) * 2024-04-08 2025-10-16 江苏恒瑞医药股份有限公司 抗tslp抗体治疗与tslp相关的炎症疾病的方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
CN1360596A (zh) 1999-02-12 2002-07-24 遗传研究所有限公司 与b7分子发生反应的人源化免疫球蛋白及应用该免疫球蛋白的治疗方法
CA2577631A1 (en) 2004-08-20 2006-03-02 Amgen Inc. Methods and compositions for treating allergic inflammation
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
AU2014346792A1 (en) 2013-11-06 2016-06-02 Abbvie Stemcentrx Llc Novel anti-claudin antibodies and methods of use
US20170002077A1 (en) 2014-03-13 2017-01-05 Prothena Biosciences Limited Combination treatment for multiple sclerosis
KR102731863B1 (ko) * 2014-03-27 2024-11-19 버드 락 바이오, 인크. 인간 카나비노이드 1(cb1) 수용체 결합 항체
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗mfi2抗體及使用方法
US9535074B2 (en) 2014-09-08 2017-01-03 Merck Sharp & Dohme Corp. Immunoassay for soluble PD-L1
JP2018080114A (ja) 2015-05-29 2018-05-24 株式会社アールテック・ウエノ 抗ヒトvap−1モノクローナル抗体
MX2017016502A (es) * 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
EP3842457A1 (en) 2015-09-09 2021-06-30 Novartis AG Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
EP3443006B1 (en) 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
EP3497120A1 (en) 2016-08-12 2019-06-19 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
EP3609917A1 (en) 2017-04-12 2020-02-19 Amgen Inc. Treatment of asthma with anti-tslp antibody
US11396538B2 (en) 2017-12-20 2022-07-26 Radimmune Therapeutics, Inc. Antibodies to centrin-1, methods of making, and uses thereof

Similar Documents

Publication Publication Date Title
JP6986965B2 (ja) 抗pd−1抗体
CA2987118C (en) A pdl-1 antibody, pharmaceutical composition thereof and use thereof
CN113527485B (zh) 抗人白细胞介素-4受体α抗体及其制备方法和应用
AU2014361473B2 (en) PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
CA2698382C (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin
KR101676269B1 (ko) 인터루킨-13 결합 단백질
JP2019172677A (ja) 抗pd−l1抗体並びにその治療及び診断のための使用
EP3892634A1 (en) Anti-cd40 antibody, antigen binding fragment and pharmaceutical use thereof
CN112513088B (zh) 抗ox40抗体、其抗原结合片段及其医药用途
CN110536903A (zh) 抗ox40抗体及其用途
CN113603784A (zh) 抗-ctla-4抗体及其使用方法
EP3632932A1 (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
JP2022533538A5 (cg-RX-API-DMAC7.html)
JP2021510064A (ja) 細胞傷害誘導治療剤
CA3228641A1 (en) Fap/cd40 binding molecule and medicinal use thereof
JP2024540148A5 (cg-RX-API-DMAC7.html)
JP7698635B2 (ja) 抗幹細胞因子抗体及びその使用方法
WO2021258337A1 (en) Human monoclonal antibodies against tigit for immune related diseases
CN115215937B (zh) 抗人masp-2抗体及其制备方法和应用
TW202515919A (zh) 抗trem2抗體及使用方法
CN114761042A (zh) Il-38特异性抗体
WO2025195358A1 (zh) Pd-1结合蛋白及医药用途
WO2022095698A1 (zh) 抗人cd38抗体及其制备方法和用途
CN121362251A (zh) 抗il-5抗体、其药物组合物及用途
WO2025031287A1 (zh) Btn3a结合蛋白及其医药用途